Article info

Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study

Authors

  1. Correspondence to Dr. Benjamin Gmeiner, Novartis Pharma GmbH, Nuremberg, 90429, Germany; benjamin.gmeiner{at}novartis.com
View Full Text

Citation

Holz FG, Abreu-Gonzalez R, Bandello F, et al
Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study

Publication history

  • Received March 8, 2021
  • Accepted July 23, 2021
  • First published August 6, 2021.

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.